Hello, my name is Jeremy and I'll be the conference operator today. At this time, I would like to welcome everyone to the Integer Holdings Corporation conference call. All lines have been placed on mute to prevent any background noise. After the speaker’s remarks, there'll be a question-and-answer session. I would now like to introduce you to your speaker Andrew Senn, Senior Vice President of Strategy, Business Development and Investor Relations. Andrew, you may begin.

Good morning, everyone. Thank you for joining us, and welcome to Integer's second quarter 2023 earnings conference call. With me today are Joe Dziedzic, President and Chief Executive Officer; and Diron Smith, Vice President Financial Planning & Analysis and Interim Chief Financial Officer. As a reminder, the results and the data we discuss today reflect the consolidated results of Integer for the periods indicated. During our call, we will discuss some non-GAAP financial measures. For a reconciliation of these non-GAAP financial measures, please refer to the appendix of today's presentation, today's earnings press release, and the trending schedules, which are available on our website at integer.net. Please note that today's presentation includes forward-looking statements. Please refer to the company's SEC filings for a discussion of the risk factors that could cause our actual results to differ materially. On today's call, Joe will provide his opening comments, and Diron will then review our financial results for the second quarter 2023, and provide an update on our full-year 2023 guidance. Joe will come back to provide his closing remarks, and then we'll open up the call for questions. With that, I'll turn the call over to Joe.

Thank you, Andrew. And thank you to everyone for joining the call today. In addition to KeyBanc, Benchmark, Piper Sandler, and Bank of America, we are excited to welcome sell-side analysts from Citi and Wells Fargo, who initiated coverage on Integer during the second quarter. We appreciate the coverage from all the sell-side analysts and are excited by the opportunity to reach more potential investors. In the second quarter, we delivered another strong quarter of year-over-year results. Sales grew 14% organically from robust customer demand across all product lines. Our adjusted operating income grew 20% while expanding margins by about 80 basis points compared to last year. We were able to deliver more products to our customers than our prior guidance assumed due to a meaningful improvement in the supply chain environment as well as a stabilizing labor market. We are encouraged by the significant supply chain improvement. However, we continue to experience pockets of supply chain risk. Based on continued strong customer demand and the improvements in supply chain and labor, we are raising our full-year outlook. We expect sales to grow 11% to 13% and adjusted operating income to grow 17% to 21% year-over-year. Free cash flow guidance is now a range of $75 million to $95 million, a strong year-over-year increase. The strategy that we developed in 2017 and began implementing in 2018 is producing above market sales growth with a pipeline to sustain growth at 200 basis points above the market. In 2023, we expect to grow operating income at 1.6x the rate of sales growth. We remain confident we can achieve our strategic financial objective of growing operating income at 2.0x the rate of sales growth through the execution of our manufacturing excellence strategies and when the supply chain and labor environment, more fully stabilize. It is an exciting time at Integer because demand remains incredibly strong. We have a robust pipeline of new products concentrated in faster-growing end markets and we are making the investments needed to deliver sustained growth. I am grateful for our associates around the world that are delivering for our customers and making a difference for patients. I'll now turn the call over to Diron.

Thank you, Joe. Good morning, everyone, and thank you again for joining today's discussion. I'll provide more details on our second quarter 2023 financial results and provide an update on our 2023 outlook. In the second quarter, we continued our strong start to 2023, with sales of $400 million. Integer delivered 14% year-over-year sales growth on both the reported and organic basis, which excludes the impact of currency fluctuations. Our sales performance reflects the continued strong customer demand across all product lines and the meaningful improvements in supply chain and direct labor. We delivered $76 million of adjusted EBITA, up $10 million compared to last year or an increase of 16%. Adjusted operating income was up 20% or $10 million versus last year as we continue to make progress on our year-over-year margin expansion. Adjusted operating income as a percent of sales increased by 76 basis points since the prior year to 15%, driven by operational efficiency improvements offsetting material inflation and annual merit increases. With adjusted net income at $38 million, we delivered $1.14 of adjusted diluted earnings per share, up $0.10 or 10% from the second quarter of 2022, benefiting from the lower fixed interest convertible notes issued in January of this year. I will share a bit more detail on the year-over-year growth and adjusted net income in a few moments. In the second quarter of 2023, sales for all four product lines delivered strong year-over-year growth due to strong customer demand and improvements in the supply chain. The Cardio & Vascular product line delivered 15% sales growth in the second quarter compared to a year ago, continued strong demand across all markets, growth in key products such as guidewires, new product ramps in electrophysiology, and supply chain improvements were drivers of the strong performance. Cardiac Rhythm Management and Neuromodulation’s second quarter sales increased 13% over the second quarter of 2022 with double-digit growth in both Cardiac Rhythm Management, and in Neuromodulation. This was driven by strong demand, including double-digit growth from emerging customers with PMA products and supply chain improvements. Advanced Surgical, Orthopedics & Portable Medical saw 17% growth in the second quarter versus a year ago, driven by increased prices and demand as a result of the continued execution of the multi-year portable medical exit announced in 2022. Additionally, Advanced Surgical and Orthopedics grew low-single-digit year-over-year. Lastly, Electrochem our non-medical segment grew 7% from a year ago, driven by strong demand in military and environmental market segments, partially offset by a decline in the energy market. Further product line details are included in the appendix of the presentation on our website at integer.net. Second quarter 2023 adjusted net income increased a total of $4 million compared to second quarter 2022, primarily due to strong sales and related operational improvements, partially offset by higher interest and taxes. In this higher interest rate environment, we incurred interest expense of approximately $4 million or $3 million tax affected more than last year. However, on a sequential basis compared to the first quarter of 2023, we reduced our interest expense by $1 million tax affected, driven by the January convertible notes issuance. Additionally, the expiration of the 10-year Malaysian tax holiday under which we have been operating is the primary driver of a higher adjusted effective tax rate for second quarter 2023 compared to the prior year. In the second quarter 2023, we generated $56 million in cash flow from operations, up $37 million from a year ago. This strong performance is driven by higher sales volumes, improving margins, our effective management of working capital, and approximately $20 million from our previously discussed accounts receivable factoring program. In the second quarter, we generated $23 million in free cash flow, inclusive of $33 million of capital expenditures. With year-to-date capital expenditures of $57 million, we are tracking to our full-year guidance of $100 million to $120 million. Net total debt in the second quarter improved by $15 million sequentially and as a result, our net total debt leverage at the end of the second quarter was 3.5x our trailing four quarter adjusted EBITDA, back within our strategic target range. We will now transition to providing an update on our full-year outlook for 2023 sales, profit, and cash. As Joe mentioned in his opening remarks with strong performance through the first half of 2023, and second quarter supply chain improvements, we are raising our full-year 2023 outlook. Starting with sales, we are increasing our outlook to 12% year-over-year growth at midpoint, with a sales range of $1,530 million to $1,550 million, an increase of 11% to 13% versus last year, up from our previous guidance of 7%. Our outlook for 2023 adjusted EBITDA is 15% to 18% growth year-over-year with a range of $294 million to $302 million, up from our previous guidance of 11% to 16% growth. We are increasing our adjusted operating income outlook by $11 million at midpoint and expect 2023 adjusted operating income to be between $224 million and $232 million, reflecting year-over-year growth of 17% to 21%. Adjusted net income is now expected to be between $143 million and $149 million reflecting a year-over-year growth of 10% to 15%, up from our previous guidance of 4% to 11%. This delivers an expected adjusted EPS outlook between $4.23 and $4.43, a growth of 9% to 14% year-over-year. Our adjusted effective tax rate remains unchanged from our previous outlook, and is projected to be between 17% and 19%. To provide more color into our outlook, our first half 2023 sales averaged $389 million comprised of an approximately $380 million quarterly run rate, plus the recovery of the prior-year supply chain delays, which were discussed in our call in April. As we enter the second half of 2023, we expect sales similar to the first half run rate of $380 million. We continue to expect adjusted operating income as a percent of sales to improve throughout the remainder of 2023 as we continue to improve manufacturing efficiencies and operate in a stabilizing direct labor environment. Moving to our 2023 cash outlook, we expect cash flow from operations between $185 million to $205 million, an increase of $5 million from our prior outlook consistent with our increase in adjusted EBITDA. Our cash flow from operations outlook includes an expected full-year impact of $35 million from accounts receivable factoring to support our Irish manufacturing facility capacity investments, which we shared during our February earnings call. Consistent with our strategy, we are maintaining our outlook on capital expenditures of $100 million to $120 million as we continue to invest in capacity expansion. As a result, we expect to generate free cash flow between $75 million and $95 million. The free cash flow generated will be used to reduce our net total debt and we expect to end the year with our leverage ratio within our target range of 2.5x to 3.5x our trailing four quarter adjusted EBITDA.

Thanks, Diron. Integer is on track for a strong year, with 22% sales growth in the first quarter, and 14% sales growth in the second quarter. Adjusted operating income was up 28% in the first quarter, and 20% in the second quarter. We are raising our 2023 outlook as we continue to execute our strategy to deliver sustained above-market growth with expanding margins. We have a strong pipeline of new products and are investing in the capacity to sustain above-market growth. We remain focused on delivering for our customers and the patients they serve to generate a premium valuation for our shareholders. Thank you for joining our call this morning. I will now turn the call back to our moderator for the Q&A portion of our call.

Awesome, thank you so much. All right, we're ready for our first question. Our first question comes from Matthew Mishan. Matthew, please go ahead.

Great, and thank you for taking the questions. I wanted to start by asking about the factors contributing to the revenue beat. Are you experiencing a level of supply chain improvement that allows you to advance some sales into 2023? Or is the procedural volume environment better than you initially anticipated for the year? Alternatively, are some new products gaining traction faster than expected?

Good morning, Matt, thank you for the questions. I'll start with the simple answer: we're meeting the procedural demand and volume that our customers have placed on us. We're in no way pulling anything forward. I'm not convinced that there was necessarily a meaningful increase in demand. We've got really good visibility to the demand from our customers. We've talked about how our backlog is now approaching a billion dollars, compared to $300 million pre-pandemic, which is a function of longer lead times across the industry and everybody placing orders further into the future. The takeaway is that gives us really good visibility in the next six to nine months. And so the increase in output in the second quarter was very much a function of supply chain improvement. We’ve talked about how we track supply chain on a daily, weekly basis. We track the number of issues and quantify the impact. Throughout the quarter, we saw continued improvement, which enabled us to meet more of the demand that we've had. We've been communicating now for six to twelve months that we have very strong demand in our backlog. It's really a function of how much of it we can meet. Our focus has been ensuring that procedure volumes have been or are meeting procedure volumes. So we don't see any of this revenue as coming from the future. We see it as meeting the demand that's been there, because supply chain has improved. We did highlight that we still have pockets of supply chain challenges, which we're managing and have factored into our second-half outlook. Now to get to the other things you asked about, we absolutely have new products from the strong product development pipeline that we've talked about and shared some of our in-process metrics. That pipeline of new products combined with our emerging customers that we've talked about has highlighted the growth that we've been experiencing there. All of that is contributing to the strong demand that we've been experiencing and had visibility to, but it's really supply chain that enabled us ultimately to get more product out the door in the second quarter. We had shared or have been sharing over the last three months since our last earnings call that demand is there. It’s really about our ability to continue to improve the supply chain and stabilize direct labor to meet more of it with our customers. What you're seeing is us being able to meet the demand that's been there and the demand remains strong, and we have confidence in our 12% sales growth at the midpoint for the full year.

All right, thank you. And then our next question comes from the line of Matthew O'Brien. Matthew, please go ahead.

Hey, this is Phil on for Matt. Congrats on the great quarter and thanks for taking our questions. Just for starters, it shows a similar vein but on the updated guidance, great to see that it's coming up more than the beat year in Q2. Where's that confidence coming from? What I'm really trying to get at is taking the guide up to let’s 12% at the midpoint. You've indicated your intention is to grow 200 basis points above the market. Do we think about the underlying market this year growing about 10%, or are you growing above that 200 basis points guidance that you've set?

Yeah, great, great question, thank you. As best we can tell as we look at the industry, we think we're growing more than the 200 basis points above the market this year. We think our ability to meet the strong demand that we've had after working through the supply chain and labor constraints means we're exceeding the 200 basis points this year. We track our customer sales into the end markets and try to correlate it. We'll see as the year progresses whether the industry is growing faster than the mid-single digits. Our weighted average growth rate based on the markets we sell into would indicate a historical mid-single-digit growth. But we think we're going much faster than the market this year. I would point to the strong product development pipeline we've talked a lot about, and those products are starting to become therapies introduced in the market, driving additional production and manufacturing revenues for us. I’d point to the emerging customers that we've talked a fair amount about that are growing from roughly $50 million in 2022 to $80 million to $100 million in 2024. We talked about that and so that's also fueling this faster than 200 basis points growth in calendar year 2023. And your next question might be about how to think about this going forward in 2024 and beyond. We still think that 200 basis points faster than the markets, which we estimate is mid-single-digit, 4% to 6%. We still think that 200 basis points faster means 6% to 8% organic growth is the right number to think about looking forward. However, we've had a really strong year, experiencing tremendous demand that we're fulfilling on and I do think 12% is well above the 200 basis points in the markets in 2023.

All right, thank you. And then our next question comes from the line of Craig Bijou. Craig, please go ahead.

Good morning, guys. Thanks for taking the questions and congrats on the strong quarter. I wanted to start with the debt. So, obviously you guys are getting back to your strategic range, and you're going to use cash flow to further reduce the debt throughout the year. So maybe just talk about kind of your M&A appetite at this point, and if with the strong underlying demand that you're seeing, if you think you need to bring on additional capacity either this year, or maybe when you look at ’24 to meet some of this demand?

Great, great, thanks for the question. Maybe the quick answer is we remain very committed to our 2.5x to 3.5x leverage. As you know, we're at 3.5x, so we're right at that spot. We think as we continue to grow EBITDA and we continue to pay down debt, which our free cash flow indicates we will continue doing, that creates capacity. We still think we have between $200 million and $250 million a year on average for acquisition capital. Obviously, at 3.5x, that means in the near term, we wouldn't be doing anything substantive or meaningful. But certainly, as that leverage comes down by year-end, and starts getting closer to the midpoint or the bottom half of our range, that creates a lot more capacity to do acquisitions. We continue to be very active in the marketplace. The activity remains high, and from the transactions that have been announced, we can see that the best assets, premium assets are still going for what we would characterize as strong multiples, premium multiples below the low 20s. When considering valuations, we still think that premium assets are being acquired at premium values. We're not looking at those size acquisitions. We've been very clear, we're staying at our 2.5x to 3.5x leverage. That puts us in that $250 million range annually. We remain very active in looking for acquisitions that fit within our strategy. We've been clear about what our strategy is and have outlined clear criteria and parameters. We're looking for acquisitions that are more tuck-in in nature, and those that will bring additional capabilities to accelerate our development work in partnership with our customers in those faster-growing end markets. The customers we're focusing on are those innovating because there is significant patient need in areas like structural heart, electrophysiology, and neurovascular. We have been investing. Our CapEx this year is heavily driven by two major expansions in Ireland, one in Galway, another in our New Ross guidewire facility, where we're spending about $40 million this year. Overall, we believe we've got around 400,000 to 500,000 square feet of available manufacturing space across our network. We're adding 80,000 square feet in guidewire facility in New Ross; 70,000 square feet in a new facility in Galway, Ireland; and more capacity in the Dominican Republic, and Tijuana facility here in the US. So we feel we have the capacity to continue to grow and support the level of growth we're projecting. 2023 is a year of elevated CapEx spend because of that. Once we enter ’24 and beyond, we expect that CapEx to come back down due to not anticipating the magnitude of facility investments.

Okay. Our next question comes from the line of Nathan Treybeck. Nathan, please go ahead.

Hi. Thanks for taking the question, congrats on a great quarter. In terms of the supply chain improvement, how would you characterize the state of the supply chain and the overall inflation environment relative to Q1 and your expectations for when it normalize? I'm thinking, like, in terms of your thoughts on getting back to your pre-COVID margins? Thanks.

Thank you for the question, Nathan. We saw significant improvements in the supply chain during the second quarter. We communicated that demand was strong, but we faced some supply chain constraints. There are still some challenges in the supply chain, and we noticed a slight increase in issues at the beginning of the third quarter. However, for the second half of this year, we are not anticipating any changes in the supply chain in our guidance. We are not in a position to predict changes in the supply chain. If improvements do occur, we believe we can increase our shipments, but we are currently assuming stability in the supply chain. Similar to our guidance after the first quarter, we observe a general trend of improvement that allowed us to deliver more in the second quarter. Regarding our goal of returning to pre-COVID margins, we aim to grow by 200 basis points or more above the markets we serve. For 2024 and beyond, we remain confident in our development pipeline and emerging customers to achieve this. We are expanding our margins this year at about 1.6 times the sales growth rate. Our target is to increase operating profit at twice the rate of sales growth. We are optimistic that once the labor environment and supply chain stabilize, we can return to growing profits at twice the sales growth rate. While I can't specify when the supply chain will fully stabilize, please understand that we are actively taking measures to enhance the supply chain. We have discussed some of our strategies, such as dual sourcing, shifting materials, and insourcing when necessary. We have various methods for managing supply chain risks. We believe we can meet our financial objectives with robust top-line growth, a strong product development pipeline, emerging customers, and continued margin expansion this year, despite ongoing challenges. We expect to reach our strategic goal of growing profits at twice the rate of sales once we have a more stable supply chain and labor market.

Great, thank you for joining the call today. As always, you can access the replay of this call on our website, as well as the presentation that was just covered. Thank you for your interest in Integer, and that concludes today's call.

Thank you. And you may now all disconnect.